Study analysis · Cancer research · 2025
Liver cancer cells use creatine to survive low oxygen – and blocking it could be a new treatment.
When liver cancer cells are in low oxygen, they take in more creatine, which helps them avoid cell death; blocking creatine uptake with a drug slows tumor growth in mice.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in cells and mice, not in people. It shows some interesting ideas about how cancer cells might survive, but we can't be sure these ideas work the same way in humans. Think of it like a clue, not proof.
What’s the bottom line?
When liver cancer cells are in low oxygen, they take in more creatine. Creatine helps them change how they use energy and avoid a special kind of cell death called 'parthanatos'.
How strong is this study?
The researchers did many different tests to check their idea, which is good. But they didn't compare groups randomly or hide which group got what treatment, so some mistakes might have slipped in. It's like a well-done science project, but not yet a strong human study.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal and in vitro study; findings cannot directly establish causation in humans. The mechanisms observed in cell lines and mouse models may not translate to human physiology.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; all funding from academic sources.
Funders
No conflict of interest statement visible in provided text; funding from Chinese government sources.
Key takeaways
- 01
In lab experiments, blocking creatine uptake made cancer cells die more easily and slowed tumor growth in mice.
- 02
This suggests that drugs blocking creatine uptake might be a new treatment for liver cancer, but human tests are needed.
Surprising findings
- Hypoxia fails to induce parthanatos in HCC cells despite causing DNA damage.Normally, DNA damage leads to cell death; hypoxia should trigger it, but the cells evade it via creatine.
Practical takeaways
While specific to liver cancer, this research highlights the importance of metabolic pathways in cancer. For now, there's no direct human application, but it underscores the potential of targeting nutrient transporters.
This is preclinical; human trials are needed. The drug RGX-202 is not yet approved.
medium confidenceWhy this study matters
Creatine: A survival fuel for liver cancer
Hypoxia, low oxygen, is common in solid tumors. This study found that hypoxia induces creatine uptake via transporter SLC6A8, which activates a pathway that prevents a type of cell death called parthanatos. Blocking SLC6A8 with RGX-202 shrank tumors in mice.
Creatine is commonly known as a supplement for athletes, but here it's used by cancer cells to survive.
A new drug target: SLC6A8
The inhibitor RGX-202 showed antitumor activity alone and synergized with lenvatinib in patient-derived xenograft and primary HCC mouse models. This suggests a potential combination therapy for liver cancer.
It's a novel approach targeting metabolism rather than directly attacking the tumor.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When liver cancer cells are in low oxygen, they take in more creatine. Creatine helps them change how they use energy and avoid a special kind of cell death called 'parthanatos'.
Research results
In lab experiments, blocking creatine uptake made cancer cells die more easily and slowed tumor growth in mice.
What this means - more context
This suggests that drugs blocking creatine uptake might be a new treatment for liver cancer, but human tests are needed.
Investigate the cross-talk between hypoxia and parthanatos (PARP1-dependent cell death) in hepatocellular carcinoma (HCC) and identify underlying mechanisms.
Hypoxia fails to induce parthanatos in HCC cells due to upregulated creatine transporter SLC6A8, leading to intracellular creatine accumulation. Creatine drives metabolic reprogramming via a SERPINE1/USP10/PKLR axis, forming a positive feedback loop with HIF1α to sustain creatine uptake and parthanatos resistance. The SLC6A8 inhibitor RGX-202 shows antitumor activity alone and synergizes with lenvatinib in mouse models.
Methods Used
In vitro HCC cell lines, patient-derived xenografts (PDX), and primary HCC mouse models. Molecular and biochemical assays to study protein interactions, enzyme activities, and metabolic changes.
Main Finding
Hypoxia-induced creatine uptake via SLC6A8 protects HCC cells from parthanatos by activating the SERPINE1/USP10/PKLR axis, and targeting SLC6A8 with RGX-202 suppresses tumor growth in preclinical models.
Confidence Level
Moderate-high: robust mechanistic data from cell lines and animal models, but requires validation in human clinical trials.
Study Flags
Red Flags
- •Preclinical models only; no human data
- •Complex pathway may not translate directly
- •Potential off-target effects of RGX-202 unknown
Surprising Findings
Hypoxia fails to induce parthanatos in HCC cells despite causing DNA damage.
Normally, DNA damage leads to cell death; hypoxia should trigger it, but the cells evade it via creatine.
Practical Takeaways
While specific to liver cancer, this research highlights the importance of metabolic pathways in cancer. For now, there's no direct human application, but it underscores the potential of targeting nutrient transporters.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Animal Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study was done in cells and mice, not in people. It shows some interesting ideas about how cancer cells might survive, but we can't be sure these ideas work the same way in humans. Think of it like a clue, not proof.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Use of multiple model systems (in vitro, patient-derived xenografts, primary mouse models)
- Mechanistic investigation with molecular and biochemical assays
- Inclusion of therapeutic intervention (RGX-202) in animal models
Weaknesses
- Lack of human clinical data
- No randomization or blinding mentioned
- Small sample sizes typical of preclinical experiments
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When liver cancer cells are in low oxygen, they take in more creatine. Creatine helps them change how they use energy and avoid a special kind of cell death called 'parthanatos'.
Research results
In lab experiments, blocking creatine uptake made cancer cells die more easily and slowed tumor growth in mice.
What this means - more context
This suggests that drugs blocking creatine uptake might be a new treatment for liver cancer, but human tests are needed.
Investigate the cross-talk between hypoxia and parthanatos (PARP1-dependent cell death) in hepatocellular carcinoma (HCC) and identify underlying mechanisms.
Hypoxia fails to induce parthanatos in HCC cells due to upregulated creatine transporter SLC6A8, leading to intracellular creatine accumulation. Creatine drives metabolic reprogramming via a SERPINE1/USP10/PKLR axis, forming a positive feedback loop with HIF1α to sustain creatine uptake and parthanatos resistance. The SLC6A8 inhibitor RGX-202 shows antitumor activity alone and synergizes with lenvatinib in mouse models.
Methods Used
In vitro HCC cell lines, patient-derived xenografts (PDX), and primary HCC mouse models. Molecular and biochemical assays to study protein interactions, enzyme activities, and metabolic changes.
Main Finding
Hypoxia-induced creatine uptake via SLC6A8 protects HCC cells from parthanatos by activating the SERPINE1/USP10/PKLR axis, and targeting SLC6A8 with RGX-202 suppresses tumor growth in preclinical models.
Confidence Level
Moderate-high: robust mechanistic data from cell lines and animal models, but requires validation in human clinical trials.
Study Flags
Red Flags
- •Preclinical models only; no human data
- •Complex pathway may not translate directly
- •Potential off-target effects of RGX-202 unknown
Surprising Findings
Hypoxia fails to induce parthanatos in HCC cells despite causing DNA damage.
Normally, DNA damage leads to cell death; hypoxia should trigger it, but the cells evade it via creatine.
Practical Takeaways
While specific to liver cancer, this research highlights the importance of metabolic pathways in cancer. For now, there's no direct human application, but it underscores the potential of targeting nutrient transporters.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Animal Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study was done in cells and mice, not in people. It shows some interesting ideas about how cancer cells might survive, but we can't be sure these ideas work the same way in humans. Think of it like a clue, not proof.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Use of multiple model systems (in vitro, patient-derived xenografts, primary mouse models)
- Mechanistic investigation with molecular and biochemical assays
- Inclusion of therapeutic intervention (RGX-202) in animal models
Weaknesses
- Lack of human clinical data
- No randomization or blinding mentioned
- Small sample sizes typical of preclinical experiments
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers did many different tests to check their idea, which is good. But they didn't compare groups randomly or hide which group got what treatment, so some mistakes might have slipped in. It's like a well-done science project, but not yet a strong human study.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal and in vitro study; findings cannot directly establish causation in humans. The mechanisms observed in cell lines and mouse models may not translate to human physiology.
No Conflicts
No conflicts of interest identified
No conflicts of interest identified; all funding from academic sources.
Funders
No conflict of interest statement visible in provided text; funding from Chinese government sources.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr. William Wallace cite this study, drawing 2 claims from it.